vida: extract claims from 2026-03-05-omada-health-fy2025-results-first-profitable-quarter

- Source: inbox/queue/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md

@@ -12,7 +12,7 @@ scope: causal
 sourcer: JMIR / Omada Health
 supports: ["healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create"]
 challenges: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics"]
-related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-long-term-persistence-ceiling-14-percent-year-two", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring"]
+related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-long-term-persistence-ceiling-14-percent-year-two", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "behavioral-glp1-companion-programs-achieve-0-8-percent-weight-maintenance-post-discontinuation-versus-11-12-percent-regain-proving-standalone-behavioral-value"]
 ---
 
 # Digital behavioral support improves GLP-1 persistence by 20 percentage points (67% vs 47% at 12 months) through integrated coaching and monitoring
@@ -60,3 +60,10 @@ Noom's microdose GLP-1Rx users showed 77.8% engagement with the app for 4+ weeks
 **Source:** Omada Health clinical outcomes data, March 2026
 
 Omada members who persisted on GLP-1 for 12 months achieved 18.4% average weight loss and 44% greater weight loss on semaglutide versus real-world evidence, suggesting behavioral support improves not just persistence but also on-medication efficacy.
+
+
+## Supporting Evidence
+
+**Source:** Omada Health FY2025 earnings report, March 5, 2026
+
+Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 47-49% comparison cohort (18-20 percentage point improvement). Persistent members achieved 18.4% average weight loss at 12 months; overall cohort 16.3% weight loss, representing 44% better outcomes than semaglutide real-world evidence. This quantifies the behavioral companion program value proposition with specific persistence and outcome data.

domains/health/employer-glp1-cash-pay-model-separates-program-cost-from-medication-cost-enabling-behavioral-support-without-drug-benefit-exposure.md

@@ -24,3 +24,10 @@ Omada Health's GLP-1 Flex Care represents a structural financial innovation in r
 **Source:** Omada Health GLP-1 Flex Care announcement, March 2026
 
 Omada's GLP-1 Flex Care is the first concrete employer product implementing this model at scale. Designed for the 55% of employers who don't cover GLP-1 medications, it allows employers to pay for behavioral support (coaching, nutrition, clinical oversight) while members purchase medications independently through cash-pay channels. This validates the theoretical model with an actual market offering launching H2 2026.
+
+
+## Supporting Evidence
+
+**Source:** Omada Health FY2025 earnings report, March 5, 2026
+
+Omada announced GLP-1 Flex Care on March 5, 2026: employer cash-pay option where employer pays for behavioral support program while member uses existing pharmacy benefits for medication. This directly addresses the covered lives decline problem by separating the drug cost burden (which employers want to avoid) from the program cost (which employers can purchase), creating a new purchasing model that bypasses the medication cost exposure barrier.

inbox/archive/health/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md

@@ -7,10 +7,13 @@ date: 2026-03-05
 domain: health
 secondary_domains: []
 format: earnings-report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-08
 priority: high
 tags: [Omada, digital-health, GLP-1, behavioral-health, atoms-to-bits, VBC, employer-market, IPO]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content